BindingDB logo
myBDB logout

71 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28072531 120 Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.EBI Arena Pharmaceuticals
28523115 59 Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DPEBI Novartis Institutes for Biomedical Research
28169162 86 Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.EBI AskAt Inc.
15013022 46 Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists [corrected].EBI Roche Palo Alto
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
27484513 1 The therapeutic journey of pyridazinone.EBI Jamia Hamdard
28105284 55 Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.EBI Ono Pharmaceutical Co., Ltd.
26985320 89 Discovery of G Protein-Biased EP2 Receptor Agonists.EBI Ono Pharmaceutical Co., Ltd.
27133594 6 Piperidine derivatives as nonprostanoid IP receptor agonists 2.EBI Toray Industries, Inc.
26996371 27 Piperidine derivatives as nonprostanoid IP receptor agonists.EBI Toray Industries, Inc.
27055938 82 Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists.EBI Ono Pharmaceutical Co., Ltd
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
25666818 95 Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat.EBI Arena Pharmaceuticals
26061158 136 A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.EBI Amgen Inc.
24900877 107 Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.EBI Merck Research Laboratories
24279689 56 Prostanoid receptor EP2 as a therapeutic target.EBI Emory University School of Medicine
24021582 52 Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.EBI Novartis Institutes for Biomedical Research
23582449 20 Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.EBI Institute of Organic Synthesis
23466604 36 Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.EBI Universit£ degli Studi di Siena
18359630 37 Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.EBI Merck Frosst Canada& Co.
18291643 76 Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.EBI Merck Frosst Centre for Therapeutic Research
16931013 138 Comparison between two classes of selective EP(3) antagonists and their biological activities.EBI Merck Frosst Centre for Therapeutic Research
15935660 3 Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2.EBI Fujisawa Pharmaceutical Co., Ltd.
15914004 34 Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.EBI Fujisawa Pharmaceutical Co., Ltd.
12643927 164 Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.EBI Merck Frosst Centre for Therapeutic Research
21982795 81 Discovery of new orally active prostaglandin D2 receptor antagonists.EBI Ono Pharmaceutical Co., Ltd
21958540 95 Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.EBI Amira Pharmaceuticals
21885288 109 Design and synthesis of new prostaglandin D2 receptor antagonists.EBI Minase Research Institute
21737285 138 Discovery of selective indole-based prostaglandin D2 receptor antagonist.EBI Minase Research Institute
21211969 42 Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.EBI USA.
21208803 81 The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid.EBI Merck Frosst Centre for Therapeutic Research
21036609 38 Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.EBI Merck Frosst Centre for Therapeutic Research
20471829 43 Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.EBI Merck Frosst Canada Ltd
20303752 143 1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists.EBI deCODE Chemistry
19836233 31 Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists.EBI deCODE Chemistry, Inc
20163116 116 The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.EBI Merck Frosst Centre for Therapeutic Research
19957930 126 Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent thatEBI deCODE Chemistry, Inc.
19608418 95 Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.EBI Amira Pharmaceuticals
19487124 39 Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.EBI GlaxoSmithKline Pharmaceuticals
 4 Molecular design of novel PGI2 agonists without PG skeleton. IVEBI TBA
 8 Molecular design of novel PGI2 agonists without PG skeleton. IIIEBI TBA
 11 Molecular design of novel PGI2 agonists without PG skeleton. IIEBI TBA
 11 Molecular design of novel PGI2 agonists without PG skeleton. IEBI TBA
19332369 43 Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain.EBI GlaxoSmithKline
19307115 89 Discovery of potent and selective DP1 receptor antagonists in the azaindole series.EBI Merck Frosst Centre for Therapeutic Research
19188065 116 3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists.EBI deCODE Chemistry
18701276 97 Highly functionalized 7-azaindoles as selective PPAR gamma modulators.EBI Merck Research Laboratories
17300164 62 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).EBI Merck Frosst Canada & Co.
16837197 14 Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6.EBI Fujisawa Pharmaceutical Co., Ltd.
16529930 96 Identification of an indole series of prostaglandin D2 receptor antagonists.EBI Merck Frosst Canada & Co.
16078846 40 Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.EBI Toray Industries Inc.
15935659 17 Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.EBI Fujisawa Pharmaceutical Co., Ltd.
15857112 55 Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.EBI Fujisawa Pharmaceutical Co., Ltd.
14643308 2 A simple stereoselective synthesis and biological evaluation of FR181157: orally active prostacyclin mimetic.EBI Fujisawa Pharmaceutical Co. Ltd
14552786 88 Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.EBI Merck Frosst Centre for Therapeutic Research
12182865 88 Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.EBI Merck Frosst Centre for Therapeutic Research
11708917 33 Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.EBI Procter & Gamble Pharmaceuticals
11454474 84 Design and synthesis of a highly selective EP4-receptor agonist. Part 2: 5-thia and 9beta-haloPG derivatives with improved stability.EBI Minase Research Institute
11454473 119 Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity.EBI Minase Research Institute
11454472 107 Design and synthesis of a highly selective EP2-receptor agonist.EBI Minase Research Institute
11266183 32 Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.EBI Merck Frosst Canada & Co.
11133092 2 A novel pyridazinone derivative as a nonprostanoid PGI2 agonist.EBI Fujisawa Pharmaceutical Co., Ltd
10715159 112 Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.EBI Procter and Gamble Pharmaceuticals
10509919 103 New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.EBI Merck Frosst Centre for Therapeutic Research
9357516 94 Bicyclo[2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane derivatives: orally active, potent, and selective prostaglandin D2 receptor antagonists.EBI Shionogi & Co., Ltd.
1370696 6 Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic.EBI Bristol-Myers Squibb Pharmaceutical Research Institute